Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO invites comments...

    CDSCO invites comments on New Drugs and Clinical Trials Rules, 2018

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-16T16:56:41+05:30  |  Updated On 16 Nov 2018 4:56 PM IST
    CDSCO invites comments on New Drugs and Clinical Trials Rules, 2018
    New Delhi: Through a recent notification CDSCO has invited stakeholders to submit their views or any objections/ suggestions on the draft New Drugs and Clinical Trials Rules, 2018. The notice also invited the stakeholders to visit CDSCO's office for personal hearing on 22.11.2018

    The Ministry of Health and Family Welfare, Government of India had issued Draft rules the New Drugs and Clinical Trials Rules, 2018 vide G.S.R.104(E) dated 1st February 2018. The Draft Rules are available on the website of the Central Drugs Standard Control Organization, of the Ministry of Health and Family Welfare. 45 days time was given to file objections and suggestion to the Draft Rules.

    As per the Hon'ble Supreme Court order dated 12.09.2018 in the subject matter; the notice adds that a corrigendum will be issued inviting objection and those who are interested may file their objection to the Draft Rules. Accordingly, a meeting was held in FDA Bhawan on 05.11.2018 with stakeholders. However, some of the parties including the petitioners have requested another date to present their views.

    Accordingly, the interested stakeholders are hereby invited to submit their views or any objections/ suggestions on the draft New Drugs and Clinical Trials Rules, 2018 and visit this office for personal hearing on 22.11.2018 at 2:00 PM, Conference Hall, 1st Floor, FDA Bhawan, Kotla Road, ITO, New Delhi-110002.

    Read Also: New Clinical Trials Rules 2018 released, check out details

    Key highlights of the Draft Rules:


    • The Draft Rules are applicable to all new drugs, investigational new drugs for human use, clinical trial, bioequivalence study, bioavailability study, and Ethics Committee.

    • Any institution or organization, which intends to conduct a clinical trial or bioavailability study or bioequivalence study, is required to have an Ethics Committee.

    • Every such Ethics Committee has to get registration from the Central Licensing Authority.

    • No person or institution or organization shall conduct a clinical trial of a new drug or investigational new drug without getting permission from the Authority. If permission granted, will remain valid for a period of two years from the date of its issue unless suspended or cancelled by the Authority.

    • An institution or organization has to conduct a clinical trial according to the protocol approved by the registered Ethics Committee.

    • If a clinical trial site does not have its own Ethics Committee, the clinical trial at that site may be initiated after getting the protocol approved from the





      • Institutional Ethics Committee of another trial site or

      • An independent Ethics Committee constituted under the Draft Rules





    • In case of termination of any clinical trial, the detailed reasons for such termination should be communicated to the Central Licencing Authority within thirty days of such termination.

    • Any report of a serious adverse event occurring during the clinical trial to a subject of the clinical trial, after due analysis, should be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the Institute where the trial has been conducted within fourteen days of its occurrence.

    • In case of an injury during a clinical trial to the subject of such trial, complete medical management and compensation should be provided by the firm and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty days of the receipt of recommendations made by Ethics Committee.

    • In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided and details of compensation provided in such cases should be intimated to the Central Licencing Authority within thirty days of receipt of the order issued by the Central Licencing Authority.

    • A license has to be obtained by the institutions or organizations for manufacturing or importing new drugs or investigational new drugs or for the manufacture of unapproved active pharmaceutical ingredient for the development of any formulation, for a clinical trial, bioavailability, bioequivalence study etc. under the Rules.

    • The institutions or organizations also have to obtain a license to manufacture or import new drugs for sale or for distribution under the Rules.


    Find the attachment for the same.

    http://www.cdsco.nic.in/writereaddata/Draft CT Rules sent for Publication.pdf
    CDSCOCentral Drugs Standard Control OrganizationClinical Trials Rules 2018draft guidelineMinistry of Health and Family WelfareNew Drugs and Clinical Trials Rules

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok